This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Register by January 24 to save up to $1200

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA
Book Now
Menu
Book

Leo Qian, PhD
Co-Founder and Vice President, Discovery Research at Entrada Therapeutics
Speaker

Profile

Ziqing “Leo” Qian, Ph.D. is co-founder and Vice President, Discovery Research at Entrada Therapeutics, a clinical stage Boston-based biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular therapeutics. Dr. Qian co-invented Entrada’s Endosomal Escape Vehicle (EEV™) platform, which is applied to the design and development of intracellular delivery of otherwise impermeable biological cargos, including oligonucleotides, proteins, and peptides.

Agenda Sessions

  • The Endosomal Escape Vehicle Platform Safely and Effectively Delivers Oligonucleotide Therapeutics to Skeletal and Cardiac Muscle Tissue for the potential treatment of Duchenne Muscular Dystrophy

    , 8:30am
    View Session

At this event

Prev
Next
Matthew Quinn
Manager, Analytical Development, Global Nucleic Acid Therapies
Novo Nordisk

See Leo at TIDES USA: Oligonucleotide & Peptide Therapeutics

Book Now